LifeCycle Pharma has established a Scientific Advisory Board for its transplantation programs. In addition, LifeCycle Pharma announces the expansion of its United States (U.S.) clinical development department with the addition of Drs. Rob Gordon and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) today announced the formation of an international Scientific Advisory Board (SAB) of experts in the field of organ transplantation. The SAB will provide counsel to the company's management team as LifeCycle Pharma expands its development programs within the area of solid organ transplantation.
The SAB consists of six internationally recognized thought leaders from the U.S. and Europe, including:
Dr. Rita R. Alloway, Director of Transplant Clinical Research, University of Cincinnati
Dr. Klemens Budde, Medical Director of Transplantation, Charite University Hospital, Berlin
Dr. Robert S. Gaston, Medical Director of Kidney & Pancreas Transplantation, University of Alabama, Birmingham
Dr. Josep M. Grinyo, Chief, Division of Nephrology, University Hospital of Bellvitge, Barcelona
Dr. John R. Lake, Director, Gastroenterology Division, University of Minnesota, Minneapolis
Dr. Marc D. Pescovitz, Professor of Surgery and Microbiology/Immunology, Indiana University Medical Center, Indianapolis
'As LifeCycle Pharma advances its product portfolio within organ transplantation, the Scientific Advisory Board will provide an instrumental role in guiding our research and development programs,' said Dr. Flemming Ornskov, President and CEO of LifeCycle. 'We have attracted established, and highly respected members of the transplantation field who will play a pivotal role in LifeCycle Pharma bringing innovation to this disease area,' added Dr.Orsnkov.
In addition, LifeCycle Pharma has strengthened its clinical development capabilities in the U.S. with the addition of Drs. Robe
rt Gordon, as Senior Director of Medical and Clinical Research, and Larry Chodoff, as Director of Medical Affairs Transplantation.
Dr. Gordon is an internationally respected transplant surgeon who has spent more then 30 years in academia and industry. He was a member of the team that was headed by the world renowned transplant surgeon, Dr. Thomas Starzl, at the University of Colorado and the University of Pittsburgh. From 1992 until he moved to industry, Dr. Gordon was Professor of Surgery and Director of the Liver Transplant Service at Emory University Hospital in Atlanta, Georgia. Most recently, Dr. Gordon was the Senior Medical Director for Transplantation at Roche Laboratories in Nutley, New Jersey.
After 17 years of practice at the Mount Sinai Medical Center in New York, New York, Dr. Larry Chodoff joined Novartis Pharmaceuticals Corporation in 1997, as Associate Director of Clinical Research, managing global research and development programs in organ transplantation and autoimmune diseases.
Prior to joining LifeCycle Pharma, Dr. Chodoff held the position of Medical Liaison in Transplantation and Immunology at Roche Laboratories. Dr. Chodoff received his Pharm.D. from the University of the Pacific School of Pharmacy in 1979.
'Their combined experience of more than 50 years of working within the area of organ transplantation will be a great asset for LifeCycle Pharma as our LCP-Tacro program enters Phase II clinical trials,' said Dr. Michael Beckert, Chief Medical Officer at LifeCycle Pharma, who will oversee the responsibilities of Drs. Rob Gordon and Larry Chodoff.
Related medicine news :1
. LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-Tacro for Organ Transplantation2
. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries3
. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries4
. Pharma cos must forge Strategic alliances5
. Medicis Pharmaceutical company enters pediatric market 6
. Pharma majors gear to supply anti-anthrax drug 7
. Pharmacies in for a dose of bitter medicine8
. Andhra Pradesh to set up Pharma City9
. Sun Pharma to launch chiral version of omeprazole soon 10
. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories 11
. Pharmacia may take 51.5 percent Abbott stake